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HEALTHCARE WORKERS PERCEPTIONS REGARDING ANTIBIOTIC USE DURING
COVID-19 PANDEMIC IN LEBANON: A CROSS-SECTIONAL STUDY
Abstract
Since the beginning of the COVID-19 pandemic, empirical antibiotics prescription has increased globally
in patients with COVID-19 for suspected or confirmed bacterial infection. Hence, concerns have been
raised about potential rise in antibiotic resistance that will create further challenges for antimicrobial
stewardship. This descriptive cross-sectional study was conducted to assess healthcare workers attitudes
and practices regarding antibiotics prescription during the COVID-19 pandemic in Lebanon. The survey
was distributed online using GOOGLE forms and included questions addressing socio-demographic
characteristics, trainings in antibiotics use and healthcare workers attitudes and practices regarding
antibiotics prescription during the pandemic. In total, 399 healthcare workers responded to the survey.
Less than half of them had already participated in antibiotic prescription trainings before or during the
pandemic. However, only 11% participated, mostly nurses, in antibiotic stewardship program. Azithromycin
was the most prescribed antibiotic with Vitamin C and Zinc used as second line treatments in COVID-19
patients. In addition, nearly two-third of the participants reported an increase in antibiotic use during the
early phase of the pandemic and considered that COVID-19 patients are receiving unnecessary antibiotics.
This study showed excessive antibiotics prescription during the COVID-19 pandemic in Lebanon that needs
to be tackled by raising awareness of antimicrobial stewardship and control measures.
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1. INTRODUCTION
Coronavirus disease 2019 (COVID-19) is caused by the new coronavirus known as severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which first appeared in Wuhan, China
in December 2019 (WHO, 2020). In Lebanon, the first case of coronavirus was confirmed on
February 21, 2020. Henceforth, Lebanon has had over 400.000 cases with worldwide cases
reaching over 120 million confirmed cases across 221 countries and territories and over 2 million
deaths. COVID-19 is characterized by typical symptoms including fever, dry cough and fatigue
and other less common symptoms such as losing smell or taste, muscle pain, nasal congestion and
nausea or vomiting (WHO, 2020). Around 80% of COVID-19 infected patients do not require
hospitalization, 15% can become severely ill and only 5% become critically ill requiring
hospitalization (WHO, 2020). Strikingly, the pandemic has been followed by an increased use and
prescription of antibiotics which will hasten antimicrobial resistance (AMR) development (Beović
et al., 2020).
COVID-19 has shifted the focus of healthcare workers and created further challenges to the
health and social care systems with huge strains being placed on global resources (Rawson et al.,
2020a). Critically ill COVID-19 patients are susceptible to develop secondary infections, however,
the empiric use of antibiotics can lead to an increase in AMR (Seaton et al., 2020). AMR is
perceived as a real global challenge threatening human and animal health. Several associations,
international agencies, and governments have emphasized the urgency of this problem (RodríguezÁlvarez et al., 2020). The pattern of AMR will unquestionably change with the emergence of
COVID-19 pandemic. Therefore, it is critical to consider and evaluate the outcomes of this
pandemic on the use of antibiotics and AMR (Rawson et al., 2020b). In addition, it is essential to
develop antimicrobial policies and guidelines by auditing the prescription of antibiotics and
implementing AMR surveillance systems and monitoring (Rawson et al., 2020b).
According to the World Health Organization (WHO), antibiotic therapy or prophylaxis
should not be used in patients with mild or moderate COVID-19 unless it is indicated (WHO,
2020). The use of antibiotics should be reserved for suspected or confirmed bacterial or fungal
respiratory co-infections in patients with COVID-19 (Rawson et al., 2020a). Studies showed that
bacterial co-infection might lead to increased morbidity and mortality in COVID-19 patients (Liu
et al., 2021). Therefore, it was expected that these patients will receive empirical antibiotic therapy
(Rawson et al., 2020a), however, most patients received the therapy before even being diagnosed
with bacterial infection (Liu et al., 2021). Moreover, recent studies showed that the rate of bacterial
co-infection in COVID-19 patients is low. Nevertheless, overprescribing of antibiotics is evident
and use of broad-spectrum antibiotics is high (Rawson et al., 2020b). For this reason, healthcare
systems must manage the optimal selection of empirical therapy. This should be followed by the
de-escalation of antibiotics when appropriate by enforcing antibiotic stewardship programs
(ASPs) (Rawson et al., 2020a). However, the basis for the empirical prescription of antibiotics in
suspected COVID-19 patients is not well identified (Seaton et al., 2020).
Implementation of effective policies and guidelines is crucial to evaluate the antimicrobial
use in COVID-19 patients and hence to mitigate the unintended consequences of the redundant
use of antibiotics and its impact on AMR (Rawson et al., 2020a; Stevens et al., 2021). Moreover,
healthcare systems must ensure that healthcare workers receive training and education in safe and
judicious antimicrobial prescribing, in addition to ASPs for the management and the optimal use
of antibiotics (Rawson et al., 2020a). Educating physicians about safe antibiotic practices could
reduce antibiotic prescribing. However, this education must extend to other health care workers
including nurses, the first healthcare workers to come into contact with COVID-19 infected
patients, and pharmacists who assist in managing this public health issue by acting as a source of
vital information to patients about COVID-19 (Bukhari et al., 2020). The combined efforts of
healthcare workers and their participation is vital to end this outbreak. Therefore, focus on
providing sufficient knowledge to physicians, nurses, and pharmacists regarding antibiotic use is
essential especially during the COVID-19 pandemic in order to diminish the collateral
consequences of this pandemic on the issue of AMR. However, there is limited data regarding
knowledge and attitudes of healthcare workers regarding antibiotic use in COVID-19 patients. To
the best of our knowledge, such a study has not been conducted in Lebanon till now. Therefore,
the purpose of this study is to assess the perception of healthcare workers regarding antibiotic use
during the COVID-19 pandemic in Lebanon.
Published by Digital Commons @ BAU, 2022
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2. METHODOLOGY
2.1 Study Design and Population
This cross-sectional study was conducted amongst physicians, nurses and pharmacists
in Lebanon. The population size was estimated at 31.000 based on data obtained from the
Lebanese order of physicians (LOP), the Order of Nurses in Lebanon (ONS) and the Order
of Pharmacists of Lebanon (OPL). The calculated sample size was found to be minimum of
385 for a desired 95% confidence interval with 5% margin of error. Considering a drop out
level of 10%, the final minimum sample size is estimated at 428. Only 400 healthcare workers
participated in the study with only one participant was excluded from the study due to missing
information. Participants were selected through convenience sampling. Healthcare workers
needed to meet the following inclusion criteria: being a physician, nurse or pharmacist
currently practicing in Lebanon for more than one year. No exclusion criteria were used.

2.2 Study Survey
The survey was adopted from previous studies (Seaton et al., 2020; Liu et al., 2021)
and adjusted to meet the study objectives. Questions were divided into 3 categories: sociodemographics, trainings in antibiotics use and healthcare workers attitudes and practices
regarding antibiotics prescription during the COVID-19 pandemic. The survey was
distributed online using GOOGLE forms through Emails and phones (WhatsApp). A pilot
study was conducted to test the integrity and comprehension of the questions.

2.3 Ethical Consideration
This study followed the guidelines of the Declaration of Helsinki on the conduct of
human research and was approved by the Institutional Review Board of the university under
the number (2021-H-0120-HS-R-0439e22). Two reminders were sent to each participant and
all participants consent online to participate in this study. All data collected were anonymous
and questionnaires were gathered and checked for completeness by the principal investigator.

2.4 Statistical Analysis
Statistical Package of Social Science (IBM SPSS, version 23) was used for data entry,
cleaning, management, and analyses. Descriptive analyses were carried out by calculating the
mean and standard deviation for continuous variables, and number and percentages for
categorical variables. Inferential statistics, mainly bivariate analyses were carried out by
using the Chi-square test for categorical variables. A p-value <0.05 was considered
significant.

3. RESULTS
3.1 Socio-demographic information of participants
399 healthcare workers participated in the study almost equally distributed between
female and male. 60.2% were physicians among whom 40.2% were specialized in internal
medicine. Most of the participants worked in private clinics, hospitals or pharmacies. 64%
took care of COVID-19 patients and 57.1% treated COVID-19 patients (Table I).
Table I: Socio-demographic information of participants. S.D is the standard deviation.

Year of Experience
Gender (399)
Female
Male
Occupation (398)
Nurse
Pharmacist
Physician
Physicians' specialty (229)
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Mean ± S.D
12.79 ± 10.76
Number

Percentage

190
209

47.6
52.4

64
94
240

16.1
23.6
60.2
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Family medicine
Pediatric
Internal medicine
Surgery/Anesthesia
Obstetrics/Gynecology
Others
Place of work (399)
Private
Public
Both
Care of patients with COVID-19 (399)
Yes
No
Treatment of patients with COVID-19 (399)
Yes
No

25
30
92
49
20
13

10.9
13.1
40.2
21.4
8.7
5.7

320
23
56

80.2
5.8
14.0

258
141

64.7
35.3

228
171

57.1
42.9

3.2 Participants' involvement in antibiotics prescription trainings and their
perception regarding the use of antibiotic during the COVID-19 pandemic
48.9% of healthcare workers had already participated in antibiotic prescription
trainings before the COVID-19 pandemic, and only 39.3% participated in similar activity
during the pandemic. Two third of participants had received seminars and lectures regarding
antibiotic prescription. However, only 11% participated in antibiotic stewardship program
during COVID-19 (Table II).
Table II: Participants’ involvement in antibiotic prescription trainings and their
perception regarding antibiotic use during the COVID-19 pandemic.

Training in antibiotic prescription before the COVID-19 pandemic
(399)
Yes
No
Training in antibiotic prescription during the COVID-19 pandemic
(399)
Yes
No
Source of training (157)
Seminars/ Lectures
Web-based education
Training in Antibiotic Stewardship Program during the COVID-19
pandemic (399)
Yes
No
Antibiotics use during the early phase of the COVID-19 pandemic
(399)
Increase
Same
Decrease
Change in antibiotic use after COVID-19 understanding (399)
Yes
No
I don’t know
Patients requested more antibiotics (399)
Yes
No
I don't know
COVID-19 patients are receiving unnecessary antibiotics (399)
Yes
No
I don't know
Inappropriate use of antibiotics in COVID-19 patients (399)
Significant
Insignificant
Antibiotics use increases mortality in COVID-19 patients (399)

Published by Digital Commons @ BAU, 2022

Number
(n)

Percentage
(%)

195
204

48.9
51.1

157
242

39.3
60.7

104
53

66.2
33.8

44
355

11
89

263
93
43

65.9
23.3
10.8

196
113
90

49.1
28.3
22.6

264
77
58

66.2
19.3
14.5

284
65
50

71.2
16.3
12.5

303
96

75.9
24.1
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Yes
No
I don't know
Prescription of antibiotics will change with the emergence of a new
strain (399)
Yes
No
I don't know
Emergence of a new strain (399)
Increase
Decrease
Drug resistance situation (399)
Yes
No
I don't know
Magnitude of emerging antibiotic resistance as a healthcare
problem (399)
Not Urgent
Urgent

57
213
129

14.3
53.4
32.3

132
155
112

33.1
38.8
28.1

115
36

76.2
23.8

318
32
49

79.7
8.0
12.3

141
258

35.3
64.7

Regarding participants' perception towards antibiotic use during the COVID-19
pandemic, 65.9% witnessed an increase in antibiotic use during the early phase of the
pandemic and almost half thought that antibiotic use has changed after the understanding of
COVID-19 (Table II).
During the COVID-19 pandemic, 71.2% of healthcare workers considered that
COVID-19 patients are receiving unnecessary antibiotics, 75.9% rated significantly
inappropriate use of antibiotics, 33.1% stated that antibiotics prescription will change with
the emergence of a new strain, 79.7% believed that prescription behavior influences the drug
resistance situation in the area, and 64.7% perceived the magnitude of emerging antibiotic
resistance as an urgent healthcare problem. However, only 14.3% found that antibiotic use
increases mortality in COVID-19 patients (Table II).

3.3 Nurses and physicians’ practices regarding antibiotic use among COVID-19
patients
66.8% of the healthcare workers followed guidelines for the antibiotic use among
COVID-19 patients, 44.8% witnessed restrictions on the use of antibiotics and 48.4% used
conducted examination on the need of antibiotics. In addition, 48.7% of them performed
antibiotic revisions based on cultures, 57.8% discontinued antibiotics administration when
needed based on symptoms relief, and 46.3% used narrow spectrum antibiotics when fever
was the common medical sign. However, only 19% of the participants performed daily
electronic audit (Table III).
Table III: Nurses and physicians practices in antibiotic use among COVID-19 patients.
Number of respondents is 304 unless indicated.

Restriction on the use of antibiotics
Yes
No
I don't know
Thorough examination
Yes
No
I don't know
Daily electronic audit
Yes
No
I don’t know
Antibiotic revision
Yes
No
I don't know
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Number
(n)

Percentage
(%)

136
100
68

44.7
32.9
22.4

147
82
75

48.4
27
24.6

58
198
48

19.1
65.1
15.8

148
106
50

48.7
34.9
16.4
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Antibiotic discontinuation
Yes
No
I don't know
Antibiotic discontinuation based on (295)
Laboratory tests
Symptoms
Both
Type of empirical use of antibiotics (301)
Narrow spectrum
Broad spectrum
Both
Following specific guidelines
Yes
No
I don't Know
Symptoms for empirical prescription of antibiotics
Fever
Expectoration
Cough
Expiratory dyspnea
Chest tightness
Weakness
COVID-19 status for empirical prescription of antibiotics
Positive test
Suspected on admission
Probable or definite nosocomial COVID-19

Number
(n)

Percentage
(%)

176
69
59

57.9
22.7
19.4

43
136
116

14.6
46.1
39.3

138
42
121

45.8
14
40.2

203
50
51

66.8
16.4
16.8

202
151
140
96
71
34

77.7
57.9
53.6
36.8
27.2
13

140
83
136

53
31.5
51.5

3.4 Healthcare workers' perceptions of antibiotics use during the COVID-19
pandemic and trainings in antibiotics prescription
The most used antibiotics were Azithromycin (87.7%), Ceftriaxone (34.6%),
Piperacillin/Tazobactam (25.4%) and Moxifloxacin (18.2%) and the least prescribed were
Gentamycin (1%) and Metronidazole (3.4%). The main route of administration was orally
(87%) followed by intravenously (63.2%). The course of antibiotics administration was
between 5 to 7 days (55%). Vitamin C (91.5%) and Zinc (89.1%) were widely used as second
line treatments in COVID-19 patients (Table IV).
Table IV: Antibiotics and other medications regimen used by healthcare workers
among COVID-19 patients.

Antibiotic
Azithromycin (367)
Ceftriaxone (318)
Piperacillin/Tazobactam (307)
Moxifloxacin (302)
Doxycyline (299)
Ciprofloxacin (297)
Vancomycin (294)
Levofloxacin (253)
Cefepime (294)
Clindamycin (292)
Ampicillin (292)
Amoxycillin (293)
Metronidazole (291)
Gentamycin (289)
Route of administration
Oral (368)
Intravenous (329)
Intramuscular (292)
Course of antibiotic administration (378)
Less than 5 days
5-7 days
8-10 days

Published by Digital Commons @ BAU, 2022

Number (n)

Percentage (%)

322
110
78
55
49
42
30
25
39
14
13
21
10
3

87.7
34.6
25.4
18.2
16.4
14.1
10.2
9.8
8.5
4.8
4.5
7.2
3.4
1

320
208
13

87
63.2
4.5

36
209
83

9.5
55.3
22.0
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10-14 days
Other first-line treatments
Vitamin C (375)
Zinc (377)
Antiviral therapy (329)
Vitamin D (386)

50

13.2

343
336
136
52

91.5
89.1
41.3
13.4

A significant association was identified between healthcare workers occupation and
stewardship training, perception of antibiotic use during the early phase of the pandemic,
antibiotics request by patients and the effect of antibiotic prescription on the emergence of
new strains (Table V). Stewardship training was significantly more observed among nurses
(23.4%) than physicians (8.3%). Moreover, pharmacists (51.1%) believed significantly, more
than physicians (27.5%), that the use of antibiotics will affect the emergence of new strains.
Healthcare occupation did not affect the other perceptions (Table V).
Table V: Differences in healthcare workers’ practices regarding antibiotic use during
the COVID-19 pandemic. * represents the variables that showed a significant
association.

Nurse
Training in antibiotic prescription
before the COVID-19 pandemic
Yes
No
Training in antibiotic prescription
during the COVID-19 pandemic
Yes
No
Training in antibiotic stewardship
program during the COVID-19
pandemic
Yes
No
Antibiotic use during the early phase of
the COVID-19 pandemic
Increase
Same
Decrease
Change in antibiotic use after COVID19 understanding
Yes
No
I don’t know
Patients requested more antibiotics
Yes
No
I don't know
COVID-19 patients are receiving
unnecessary antibiotics
Yes
No
I don't know
Inappropriate use of antibiotics in
COVID-19 patients
Significant
Insignificant
Antibiotic use increases mortality in
COVID-19 patients
Yes
No
I don't know
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Number (Percentage)
Physician
Pharmacist

p value
0.38

30 (46.9)
34 (53)

124 (51.7)
116 (48.3)

41 (43.6)
53 (56.4)
0.2

23 (35.9)
61 (64.1)

103 (42.9)
137 (57.1)

31 (33)
63 (67)
0.002

15 (23.4) *
49 (76.6)

20 (8.3) *
220 (91.7)

9 (9.6)
85 (90.4)
0.015

32 (50) *
23 (35.9)
9 (14.1)

158 (65.8)
55 (22.9)
27 (11.3)

72 (76.6) *
15 (16)
7 (7.4)
0.065

30 (46.9)
13 (20.3)
21 (32.8)

114 (47.5)
70 (29.2)
56 (23.3)

52 (55.3)
29 (30.9)
13 (13.8)

40 (62.5)
6 (9.4)
18 (28.1) *

162 (67.5)
57 (23.8)
21 (8.8) *

61 (64.9)
14 (14.9)
19 (20.2)

0.000

0.36
39 (60.9)
13 (20.3)
12 (18.8)

174 (72.5)
38 (15.8)
28 (11.7)

70 (74.5)
14 (14.9)
10 (10.6)
0.42

45 (70.3)
19 (29.7)

187 (77.9)
53 (22.1)

70 (74.5)
24 (25.5)
0.07

10 (15.6)
39 (60.9)
15 (23.4)

27 (11.3)
129 (53.8)
84 (35)

20 (21.3)
44 (46.8)
30 (31.9)
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Prescription of antibiotics will change
with the emergence of a new strain
Yes
No
I don't know
Drug resistance situation
Yes
No
I don't know
Magnitude of emerging antibiotic
resistance as a healthcare problem
Not Urgent
Urgent

0.01
17 (26.6)
25 (39.1)
22 (34.4)

66 (27.5) *
104 (43.3)
70 (29.2)

48 (51.1)*
26 (27.7)
20 (21.3)

43 (67.2)
7 (10.9)
14 (21.8)

195 (81.3)
17 (7.1)
28 (11.7)

79 (84)
8 (8.5)
7 (7.4)

0.057

0.76
21 (32.8)
43 (67.2)

84 (35)
156 (65)

36 (38.3)
58 (61.7)

When determining the effect of antibiotics training on healthcare workers perception
regarding antibiotic use, an increase in healthcare workers knowledge regarding the
unnecessary use of antibiotics and influence on drug resistance was observed. Additionally,
data in this study revealed a significant association with healthcare belief that antibiotic
prescription would increase mortality (Table VI).
Table VI: Association between antibiotic prescription training and perception of
antibiotic use during the COVID-19 pandemic. * represents the variables that showed a
significant association.
Number (Percentage)
Training in antibiotic prescription
COVID-19 patients are receiving unnecessary
antibiotics
Yes
No
I don't know
Inappropriate use of antibiotics in COVID-19
patients
Significant
Insignificant
Antibiotic use increases mortality in COVID-19
patients
Yes
No
I don't know

Yes

No
0.004

122 (77.7)
26 (16.6)
9 (5.7) *

162 (66.9)
39 (16.1)
41 (16.9) *
0.72

121 (77.1)
36 (22.9)

182 (75.2)
60 (24.8)
0.001

32 (20.4)*
88 (56.1)
37 (23.6)

25 (10.3) *
125 (51.7)
92 (38)

Prescription of antibiotics will change with the
emergence of a new strain
Yes
No
I don't know

61 (38.9)
58 (36.9)
38 (24.2)

71 (29.3)
97 (40.1)
74 (30.6)

Drug resistance situation
Yes
No
I don't know

129 (82.2)
17 (10.8)
11 (7) *

189 (78.1)
15 (6.2)
38 (15.7) *

Magnitude of emerging antibiotic resistance as a
healthcare problem
Not Urgent
Urgent

Published by Digital Commons @ BAU, 2022

p value

0.12

0.01

0.07
64 (40.8)
93 (59.2)

77 (31.8)
165 (68.2)
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3.5 Impact of ASP on nurses and physicians' perception regarding antibiotic use
among COVID-19 patients
ASP training during the COVID-19 pandemic among nurses and physicians was
significantly associated with the following practices: training in antibiotic use before and after
the COVID-19 pandemic, restriction on the use of antibiotics, examination conducted on the
need of antibiotics, daily electronic audit, antibiotic revision and following guidelines
regarding the use of antibiotics in COVID-19 patients. All these practices were significantly
enhanced among nurses and physicians that had participated in ASP (Tables VII).
Table VII: Association between stewardship training and antibiotic prescription
practice among nurses and physicians.

Stewardship training
Training in antibiotic prescription
before the COVID-19 pandemic
Yes
No
Training in antibiotic prescription
during the COVID-19 pandemic
Yes
No
Restriction on the use of antibiotics
Yes
No
I don't know
Thorough examination
Yes
No
I don't know
Daily electronic audit
Yes
No
I don’t know
Antibiotic revision
Yes
No
I don't know
Antibiotic discontinuation
Yes
No
I don't know
Following specific guidelines
Yes
No
I don't Know

Number (Percentage)
Yes
No

p value
0.000

29 (82.9)
6 (17.1)

125 (46.1)
146 (53.9)
0.000

28 (80)
7 (20)

98 (36.2)
173 (63.8)

24 (68.6)
8 (22.9)
3 (8.6)

113 (41.7)
93 (34.3)
65 (24)

26 (74.3)
6 (17.1)
3 (8.6) 73

122 (45)
76 (28)
73 (26.9)

19 (54.3)
13 (37.1)
3 (8.6)

39 (14.4)
186 (68.6)
46 (17)

28 (80)
3 (8.6)
4 (11.4)

121 (44.6)
103 (38)
47 (17.3)

18 (51.4)
12 (34.3)
5 (14.3)

159 (58.7)
58 (21.4)
54 (19.9)

30 (85.7)
2 (5.7)
3 (8.6)

173 (63.8)
50 (18.5)
48 (17.7)

0.008

0.004

0.000

0.000

0.21

0.034

4. DISCUSSION
The COVID-19 pandemic is currently a major health threat exhibiting a chaotic and
profound impact on all aspects of health care including the steady increase in antimicrobial
resistance. It is worth mentioning that the irrational use of antibiotics in COVID-19 patients will
exacerbate the concern of AMR beyond the COVID-19 pandemic, thus the establishment of an
antibiotic stewardship program is crucial to tackle this issue while promoting the optimization of
antibiotic therapy. Currently, studies conducted among healthcare providers on antibiotic use
during the COVID-19 pandemic are scarce. In this regard, we conducted this study to assess
knowledge, attitudes, and practices regarding prescribing patterns of antibiotics during the
COVID-19 pandemic among Lebanese healthcare providers.
Presently, there are no drugs or therapeutics approved for COVID-19 disease. Recent
clinical evidence has emphasized the supportive role of nutritional supplementation in COVID-19
patients. In our study, the most common supplements prescribed as immune system boosters were
Vitamin C (91.5%) and Zinc (89.1%). Vitamin C has antimicrobial and immunomodulatory
properties and works as scavenger of reactive oxygen species (Mousavi et al., 2019; Meščić Macan
https://digitalcommons.bau.edu.lb/hwbjournal/vol4/iss2/10
DOI: https://www.doi.org/10.54729/YDEL5984

8

nd AZAKIR: HEALTHCARE WORKERS PERCEPTIONS REGARDING ANTIBIOTIC USE DURING COVID-19 PANDEMIC IN LEBANON: A CROSS-SECTIONAL

et al., 2019). It can counteract the cytokine storm that diminishes the host immune response
exacerbating the acute respiratory distress syndrome (ARDS) (Härtel et al., 2004; Jovic et al.,
2020; Feyaerts & Luyten, 2020). The prescription of both Vitamin C and Zinc in addition to other
mineral supplementation or “immunonutrition” (Vitamins A, B, D and E) is crucial to mitigate the
COVID-19 devastating effects (Jovic et al., 2020).
Regarding the antibiotic therapy during the COVID-19 pandemic, the findings of this study
showed an increase in antibiotic use during this period. In addition, the participants reported the
administration of oral antibiotics as empiric therapy in patients with probable or definite
nosocomial COVID-19 (51.5%), or patients who tested positive for COVID-19 (53%). Fever was
the most common symptom (77.7%) that guides the prescription of empiric antibiotic regimen to
non-hospitalized and hospitalized patients. The increase of antibiotic use in this study is consistent
with a multi-hospital cohort study, conducted in Michigan, which showed an increase in the
prescription of early empiric antibacterial therapy (56.6% of the hospitalized COVID-19 patients),
whilst only 3.5% were diagnosed with bacterial infection (Vaughn et al., 2021). Similar findings
were reported in other studies emphasizing on the early empiric antibiotics prescription in patients
hospitalized with COVID-19 (Rawson et al., 2020a; Guan et al., 2020; Langford et al., 2020;
Lansbury et al., 2020).
Although two-thirds of the healthcare providers that participated in our study declared that
they follow specific guidelines in antibiotic administration, data showed that the prescription was
not evidence-based and designed without prior culture-proven identification of bacterial
pneumonia to differentiate it from COVID-19 pneumonia. The widespread of antibiotic use in
Lebanon and other countries may stem from the clinicians experience that treated patients who
had bacterial coinfections during influenza pandemic (Nestler et al., 2021).
Moreover, the participants reported that azithromycin was the first most commonly
prescribed antibiotic to treat COVID-19 patients, followed by ceftriaxone. The widespread
prescription of azithromycin, worldwide, was reported mostly during the early phase of the
pandemic; however, the evaluation of the practice patterns of the surveyed Lebanese healthcare
providers revealed continued prescribing of this antibiotic. Azithromycin is a semisynthetic
macrolide with a broad-spectrum bacteriostatic activity against Gram-positive bacteria and some
community-acquired Gram-negative pathogens. Beyond their antimicrobial properties, the
effectiveness of macrolides use in respiratory viral infections is controversial. Macrolide
antibiotics are reported for their anti-inflammatory and immunomodulatory effects, they mitigate
the production of pro-inflammatory cytokines and attenuate virus-induced exacerbations (Min &
Jang, 2012). These striking features render them promising drug candidates for treating the
cytokine storm which is a prominent hallmark of severe influenza A and COVID‐19 diseases. Our
findings are consistent with other studies that showed increased use of broad-spectrum antibiotics
including azithromycin and ceftriaxone during the early phase of the pandemic (Nestler et al.,
2021; Abelenda-Alonso et al., 2020). Additionally, a recent Canadian meta-analysis revealed
similar antibiotic prescribing practices to nearly three-quarters of patients with COVID-19,
whereas the prevalence of bacterial co-infections was 8.6% (Langford et al., 2020). Recent studies
reported a clinical efficacy of the hydroxychloroquine and azithromycin combined treatment for
virus elimination in addition to a decrease in mortality in patients with severe COVID-19 (Arshad
et al., 2020; Gautret et al., 2020). Furthermore, a retrospective observational study conducted in
an American tertiary-care academic medical center reported that approximately two-thirds of
COVID-19–confirmed patients received an antibiotic. It also demonstrated an increase in both
azithromycin and ceftriaxone use for COVID-19 patient care teams compared to pre–COVID-19
levels, but followed by significant antimicrobial use reduction, resulting from the implementation
of clinical guidance team who recommended the cessation of azithromycin use for COVID-19
treatment alone, and the discontinuation of antibiotic therapy in patients with confirmed COVID19. However, ceftriaxone use in that study did not show any significant change (Staub et al., 2021).
Despite the fact that they improve the clinical outcomes of hospitalized patients with severe
COVID-19, there is no significant evidence on the efficacy of including macrolides to the
treatment regimen for COVID-19 patients. A randomized clinical trial, conducted in Brazil,
showed that the use of azithromycin in a combination therapy with hydroxychloroquine has no
effect on the clinical outcomes of patients with severe COVID-19 (Furtado et al., 2020). Another
observation study conducted in a French teaching hospital reported a significant reduction in the
prescription of the combination of hydroxychloroquine with azithromycin from the beginning of
Published by Digital Commons @ BAU, 2022
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April 2020 (Gourieux et al., 2021). Notably, studies showed that prevalence of bacterial
coinfection is very low (<5%) and antibiotics should not be routinely used unless a bacterial
coinfection is suspected. Consequently, the WHO and Chinese guidelines discouraged
inappropriate and routine empirical antibiotic treatment, especially the broad-spectrum
antibacterial drugs, in patients without suspected or confirmed severe COVID-19 (WHO, 2020;
Zhang et al., 2020).
In this study, more than two thirds of the participants agreed that unneeded and overprescribed antibiotics across health care settings will contribute to antimicrobial resistance; and
described the emergence of antibiotic resistance as an urgent healthcare issue. In response to the
pandemic, healthcare settings have rapidly implemented prophylactic antibiotic regimen in the
first-line treatment for COVID-19. This adaptation may be explained by disease severity on
admission despite few reports of bacterial coinfection. Furthermore, most of the surveyed nurses
and physicians in our study reported that they don’t perform daily electronic audit, and nearly half
of them don’t conduct a thorough examination regarding whether a patient is in need of antibiotics
and don’t incorporate formulary restrictions into the drug ordering process. In addition, they don’t
perform culture-based revisions but the discontinuation of antibiotics therapy is based on
symptoms relief. All these findings could be explained by the limited training and education
provided on antibiotic stewardship program, since only 11% of the healthcare providers had
participated in this program. In this regard, antibiotic stewardship training program during the
COVID-19 pandemic among nurses and physicians was significantly associated with training,
restrictions on antibiotic use, adherence to practice guidelines, and other patterns related to
monitoring of antimicrobial use. These practices were significantly improved among nurses that
had participated in ASP. Hence, excessive antibiotics prescription may be explained by lack of
attention to the implementation and support of stewardship in healthcare settings that could
improve the rational and judicious use of antibiotics. Engagement and education of healthcare
providers is crucial to mitigate inappropriate use of antibiotics during the COVID-19 pandemic,
and thus antimicrobial resistance (Liew et al., 2020).
The present study is the first nationwide descriptive analysis that reveals the current
situation and reflects the antibiotic prescribing practices among Lebanese healthcare providers
during the COVID-19 pandemic. However, the interpretation of our findings must be considered
in the context of limitations. First, the cross-sectional design of the survey demonstrated
associations with no evidence of temporal relationships. Second, we did not have data on
secondary bacterial infections that could further explain the use of antibiotics. Third, proportional
allocation of healthcare practitioners was not reached during data collection.
5. CONCLUSION
The present study evaluated the perception of healthcare workers regarding antibiotic use
during the COVID-19 pandemic in Lebanon. The findings showed that less than half of the
participants had already participated in antibiotic prescription trainings. However, the
participation in antibiotic stewardship program was limited. In addition, nearly two-third of the
participants reported an increase in antibiotic use, especially Azithromycin, during the early phase
of the COVID-19 pandemic. This study highlights the urgent need to implement antimicrobial
stewardship programs in health systems to halt the spread of antibiotic resistance and effectively
handle any future pandemics and health risks in the country.
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